Latest Oncology News

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

Kristi Rosa

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

June 29th 2022

Jason Harris

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

Kristi Rosa

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

Kristi Rosa

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

June 29th 2022

Chris Ryan

Socazolimab produced encouraging response rates with an acceptable safety profile in patients with recurrent or metastatic cervical cancer, irrespective of PD-L1 status, according to findings from the dose-expansion portion of a phase 1 trial.

Latest Oncology Videos

All Oncology News

Dr. Stein on the KOMET-001 Trial in Relapsed/Refractory AML

June 10th 2022

Eytan M. Stein, MD

Eytan M. Stein, MD, discusses the phase 1/2 KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Epcoritamab Plus R-DHAX/C Demonstrates High Response Rates and Manageable Safety in DLBCL

June 10th 2022

Ashling Wahner

Epcoritamab plus rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin displayed encouraging responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are eligible for autologous stem cell transplant, according to preliminary results from arm 4 of the phase 1b/2 EPCORE NHL-2 trial.

Pirtobrutinib Under Exploration in Patients with Previously Treated MCL

June 10th 2022

Ryan Scott

Single-agent pirtobrutinib is being investigated for safety and efficacy in heavily pretreated, BTK inhibitor–naïve patients with mantle cell lymphoma in the ongoing phase 3 BRUIN-MCL-321 trial.

NPM1 Mutations, MRD Responses Linked to Long-Term Survival Benefits With Azacitidine in AML

June 10th 2022

Chris Ryan

Oral azacitidine was associated with improved long-term survival in patients with acute myeloid leukemia who harbored NPM1 mutations, had intermediate-risk cytogenetics at diagnosis, had a longer treatment duration, or a minimal residual disease response during treatment.

Sintilimab Plus Decitabine Demonstrates 62% ORR in Untreated, Higher-Risk MDS

June 10th 2022

Caroline Seymour

The combination of the PD-1 antibody sintilimab and decitabine elicited potent clinical activity and manageable safety with no grade 4 or 5 treatment-related adverse effects as frontline therapy in patients with higher-risk myelodysplastic syndrome, according to preliminary results from a phase 2 trial.

Updated CAPTIVATE Data Underscore Long-Term Benefits of Fixed-Duration Ibrutinib/Venetoclax in CLL/SLL

June 10th 2022

Kristi Rosa

The fixed-duration, frontline combination comprised of ibrutinib and venetoclax continued to produce deep, durable responses with a clinically meaningful progression-free survival benefit in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and Beyond

June 10th 2022

Jane de Lartigue, PhD

B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.

Yale Scientists Develop Precision Medicine Approach to Metabolic Therapy for Breast Cancer

June 10th 2022

Yale Cancer Center

Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.

Dr. Castillo on the CLOVER-WaM Trial in Waldenström Macroglobulinemia

June 10th 2022

Jorge J. Castillo, MD

Jorge J. Castillo, MD, discusses the phase 2 CLOVER WaM trial in Waldenström macroglobulinemia.

First-Line Toripalimab Plus Chemotherapy Elicits Survival Benefit in NSCLC Irrespective of PD-L1 Status

June 9th 2022

Chris Ryan

Adding toripalimab to chemotherapy in the frontline setting demonstrated improved progression-free survival vs placebo plus chemotherapy in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.

Novel Chemoimmunotherapy Combinations Build on Established Treatment Standards in Lung Cancer

June 9th 2022

Ashling Wahner

Lawrence E. Feldman, MD, discusses shifting standards of care in small cell lung cancer, plus the implications of the phase 3 LEAP-006 and LEAP-008 trials in non–small cell lung cancer.

Zanubrutinib Continues to Provide Clinically Meaningful Advantages Over Ibrutinib in Waldenström Macroglobulinemia

June 9th 2022

Chris Ryan

Zanubrutinib continued to demonstrate a higher complete response or very good partial response rate and less off-target activity compared with ibrutinib in patients with MYD88-mutated Waldenström macroglobulinemia.

FDA Approves FoundationOne CDx as a Companion Diagnostic for Entrectinib in ROS1+ and NTRK+ Cancers

June 9th 2022

Jason Harris

The FDA has given the green light to FoundationOne CDx to identify patients with ROS1 fusion–positive non–small cell lung cancer or NTRK fusion–positive cancers who might be candidates for entrectinib.

Florida Cancer Specialists & Research Institute Welcomes Medical Oncologist Ibrahim Sadek, MD to The Villages

June 9th 2022

Florida Cancer Specialists

Medical oncologist Ibrahim Sadek, MD has joined Florida Cancer Specialists & Research Institute.

Updated RATIONALE-309 Data Support Use of Tislelizumab/Chemo in Frontline Recurrent/Metastatic Nasopharyngeal Cancer

June 9th 2022

Wayne Kuznar

Tislelizumab plus chemotherapy continued to improve progression-free survival over chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated data from the RATIONALE-309 trial.

See All News